Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 253

1.
2.

Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban.

Potpara TS, Polovina MM, Licina MM, Stojanovic RM, Prostran MS, Lip GY.

Adv Ther. 2012 Jun;29(6):491-507. doi: 10.1007/s12325-012-0026-8. Epub 2012 Jun 7. Review.

PMID:
22684583
3.

Emerging anticoagulant therapies for atrial fibrillation: new options, new challenges.

Mangiafico RA, Mangiafico M.

Curr Med Chem. 2012;19(27):4688-98. Review.

PMID:
22830344
4.

Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation.

Lip GY, Larsen TB, Skjøth F, Rasmussen LH.

J Am Coll Cardiol. 2012 Aug 21;60(8):738-46. doi: 10.1016/j.jacc.2012.03.019. Epub 2012 May 9.

5.

The king is dead (warfarin): direct thrombin and factor Xa inhibitors: the next Diadochian War?

Diener HC, Eikelboom J, Granger CB, Hacke W.

Int J Stroke. 2012 Feb;7(2):139-41. doi: 10.1111/j.1747-4949.2011.00739.x.

PMID:
22264366
6.

Direct thrombin and factor Xa inhibition for stroke prevention in patients with atrial fibrillation.

Galanis T, Merli GJ.

Hosp Pract (1995). 2013 Feb;41(1):26-36. doi: 10.3810/hp.2013.02.1010. Review.

PMID:
23466965
7.

An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation.

Mantha S, Ansell J.

Thromb Haemost. 2012 Sep;108(3):476-84. doi: 10.1160/TH12-02-0093. Epub 2012 Jun 28. Review.

PMID:
22740145
8.

Disadvantages of VKA and requirements for novel anticoagulants.

Shameem R, Ansell J.

Best Pract Res Clin Haematol. 2013 Jun;26(2):103-14. doi: 10.1016/j.beha.2013.07.009. Epub 2013 Jul 23. Review.

PMID:
23953899
9.

New oral anticoagulants for atrial fibrillation: a review of clinical trials.

O'Dell KM, Igawa D, Hsin J.

Clin Ther. 2012 Apr;34(4):894-901. doi: 10.1016/j.clinthera.2012.01.019. Epub 2012 Mar 13. Review.

PMID:
22417716
10.

Stroke prevention in atrial fibrillation: impact of novel oral anticoagulants.

Haft JI.

Clin Appl Thromb Hemost. 2013 Jun;19(3):241-8. doi: 10.1177/1076029612458148. Epub 2012 Sep 4. Review.

PMID:
22952215
11.

Dabigatran for stroke prevention in atrial fibrillation: the RE-LY trial.

Paikin JS, Haroun MJ, Eikelboom JW.

Expert Rev Cardiovasc Ther. 2011 Mar;9(3):279-86. doi: 10.1586/erc.11.21.

PMID:
21438804
12.

[Dabigatran as an alternative to warfarin for the prevention of thromboembolism in atrial fibrillation].

De Caterina R, Renda G.

G Ital Cardiol (Rome). 2012 Nov;13(11 Suppl 1):19S-27S. doi: 10.1714/1179.13063. Italian.

PMID:
23160016
13.

Dabigatran etexilate: an oral direct thrombin inhibitor for prophylaxis and treatment of thromboembolic diseases.

Baetz BE, Spinler SA.

Pharmacotherapy. 2008 Nov;28(11):1354-73. doi: 10.1592/phco.28.11.1354. Review.

PMID:
18956996
14.

Dabigatran etexilate, a new oral direct thrombin inhibitor, for stroke prevention in patients with atrial fibrillation.

Siddiqui FM, Qureshi AI.

Expert Opin Pharmacother. 2010 Jun;11(8):1403-11. doi: 10.1517/14656566.2010.482931. Review.

PMID:
20446854
15.

A review of oral anticoagulants in patients with atrial fibrillation.

Greenspon AJ.

Postgrad Med. 2012 Nov;124(6):7-16. doi: 10.3810/pgm.2012.11.2608. Review.

PMID:
23322134
16.

[Effective, safe stroke prevention with novel oral anticoagulants in patients with atrial fibrillation. Focus on dabigatran].

Szapary L, Fehér G, Bosnyák E, Deli G, Csécsei P.

Ideggyogy Sz. 2013 May 30;66(5-6):165-74. Review. Hungarian.

PMID:
23909016
17.

Stroke prevention in atrial fibrillation: do we still need warfarin?

Diener HC, Weber R, Lip GY, Hohnloser SH.

Curr Opin Neurol. 2012 Feb;25(1):27-35. doi: 10.1097/WCO.0b013e32834e604a. Review.

PMID:
22143201
18.

Dabigatran etexilate versus warfarin as the oral anticoagulant of choice? A review of clinical data.

Ma TK, Yan BP, Lam YY.

Pharmacol Ther. 2011 Feb;129(2):185-94. doi: 10.1016/j.pharmthera.2010.09.005. Epub 2010 Oct 12. Review.

PMID:
20920530
19.

Dabigatran and factor Xa inhibitors for stroke prevention in patients with nonvalvular atrial fibrillation.

Uchiyama S, Ibayashi S, Matsumoto M, Nagao T, Nagata K, Nakagawara J, Tanahashi N, Tanaka K, Toyoda K, Yasaka M.

J Stroke Cerebrovasc Dis. 2012 Apr;21(3):165-73. doi: 10.1016/j.jstrokecerebrovasdis.2012.01.011. Review.

PMID:
22440950
20.

Insights from the dabigatran versus warfarin in patients with atrial fibrillation (RE-LY) trial.

Khoo CW, Lip GY.

Expert Opin Pharmacother. 2010 Mar;11(4):685-7. doi: 10.1517/14656560903530691.

PMID:
20105114

Supplemental Content

Support Center